Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpiwenshen cataplasm is a traditional Chinese medicine (TCM) hospital preparation developed through a collaboration between Shunyi Hospital and the Beijing Hospital of Traditional Chinese Medicine. It is specifically formulated for the treatment of irritable bowel syndrome with diarrhea (IBS-D), particularly for patients presenting with the Spleen and Kidney Yang Deficiency pattern in TCM theory. The medication is designed as a cataplasm (a medicated adhesive patch) for topical application to specific acupoints, most notably the Shenque (CV8) point located at the navel. This transdermal delivery system allows for the absorption of active herbal constituents that aim to regulate gastrointestinal motility, reduce visceral hypersensitivity, and restore the balance of the gut-brain axis. The formulation typically integrates multiple herbal extracts known for their warming and tonifying properties to address the underlying physiological imbalances associated with chronic diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpiwenshen cataplasm.